Amyotrophic lateral sclerosis care in Saudi Arabia: A survey of providers’ perceptions

Abuzinadah, Ahmad R.; Alshareef, Aysha A.; AlKutbi, Abdullah; Bamaga, Ahmed K.; Shehri, Ali Al; Algahtani, Hussein; Cupler, Edward; Alanazy, Mohammed H.

doi:10.1002/brb3.1795

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although riluzole is typically safe and well tolerated in clinical practice, its effectiveness in ALS is limited, extending tracheostomy-free life by only 2-3 months [52]. The free radical scavenger edaravone, which helps slow the course of the disease, was licensed in 2017 as an intravenous infusion at a dose of 60 mg/day [53]. Even though the exact mechanism of action of the beneficial properties of edaravone against ALS is unknown, its therapeutic effects are deemed to be due to its antioxidant properties.…”

Section: Amyotrophic Lateral Sclerosis (Als)mentioning

confidence: 99%

Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications

Giri,

Banerjee,

Ghosal

et al. 2024

IJMS

View full text Add to dashboard Cite

Neurodegenerative disorders (NDs) have become increasingly common during the past three decades. Approximately 15% of the total population of the world is affected by some form of NDs, resulting in physical and cognitive disability. The most common NDs include Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. Although NDs are caused by a complex interaction of genetic, environmental, and lifestyle variables, neuroinflammation is known to be associated with all NDs, often leading to permanent damage to neurons of the central nervous system. Furthermore, numerous emerging pieces of evidence have demonstrated that inflammation not only supports the progression of NDs but can also serve as an initiator. Hence, various medicines capable of preventing or reducing neuroinflammation have been investigated as ND treatments. While anti-inflammatory medicine has shown promising benefits in several preclinical models, clinical outcomes are often questionable. In this review, we discuss various NDs with their current treatment strategies, the role of neuroinflammation in the pathophysiology of NDs, and the use of anti-inflammatory agents as a potential therapeutic option.

show abstract

Section: Amyotrophic Lateral Sclerosis (Als)mentioning

confidence: 99%

Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications

Giri,

Banerjee,

Ghosal

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Communication About End of Life for Patients Living With Amyotrophic Lateral Sclerosis: A Scoping Review of the Empirical Evidence

et al. 2021

View full text Add to dashboard Cite

Background: Communication about end of life, including advance care planning, life-sustaining therapies, palliative care, and end-of-life options, is critical for the clinical management of amyotrophic lateral sclerosis patients. The empirical evidence base for this communication has not been systematically examined.Objective: To support evidence-based communication guidance by (1) analyzing the scope and nature of research on health communication about end of life for amyotrophic lateral sclerosis; and (2) summarizing resultant recommendations.Methods: A scoping review of empirical literature was conducted following recommended practices. Fifteen health-related and three legal databases were searched; 296 articles were screened for inclusion/exclusion criteria; and quantitative data extraction and analysis was conducted on 211 articles with qualitative analysis on a subset of 110 articles that focused primarily on health communication. Analyses summarized article characteristics, themes, and recommendations.Results: Analysis indicated a multidisciplinary but limited evidence base. Most reviewed articles addressed end-of-life communication as a peripheral focus of investigation. Generic communication skills are important; however, substantive and sufficient disease-related information, including symptom management and assistive devices, is critical to discussions about end of life. Few articles discussed communication about specific end-of-life options. Communication recommendations in analyzed articles draw attention to communication processes, style and content but lack the systematized guidance needed for clinical practice.Conclusions: This review of primary research articles highlights the limited evidence-base and consequent need for systematic, empirical investigation to inform effective communication about end of life for those with amyotrophic lateral sclerosis. This will provide a foundation for actionable, evidence-based communication guidelines about end of life. Implications for research, policy, and practice are discussed.

show abstract

Amyotrophic lateral sclerosis care in Saudi Arabia: A survey of providers’ perceptions

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 2 publications

References 27 publications

Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications

Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications

Communication About End of Life for Patients Living With Amyotrophic Lateral Sclerosis: A Scoping Review of the Empirical Evidence

Contact Info

Product

Resources

About